Cardax is a development stage biopharmaceutical company primarily focused on the development of pharmaceuticals for chronic diseases driven by inflammation.

May 5, 2006:

Cardax Pharmaceuticals, Inc. (“Holdings”) acquired the intellectual property and other assets regarding certain astaxanthin technologies from Hawaii Biotech, Inc., a Delaware corporation (“HBI”), in exchange for shares of common stock of Holdings, shares of preferred stock of Holdings, options to purchase shares of common stock of Holdings and the assumption by Holdings of certain liabilities of HBI.  At this date, Holdings became a separate company with the initial life-science astaxanthin technologies

May 5, 2006 to May 31, 2013:

Holdings continued the research and development of astaxanthin technologies and related compounds and raised capital primarily through the issuance of debt securities.

January 30, 2012:

We were incorporated in Delaware under the name “Koffee Korner Inc.”  At this time, we acquired all the capital stock of Koffee Korner’s Inc, a Texas corporation (“Koffee Sub”), which operated as a single location retailer of specialty coffee in Houston, Texas.

May 16, 2013:

Cardax Pharma, Inc. (“Pharma”) was formed as a wholly owned subsidiary of Holdings.

May 31, 2013:

Holdings contributed its assets to Pharma in exchange for all of the capital stock of Pharma and the assumption by Pharma of all of the liabilities of Holdings.

May 31, 2013 to February 7, 2014:

Pharma continued the business of Holdings including the research and development of consumer health and pharmaceutical technologies and the commercialization of our technologies for products, and raised capital through the offering of senior secured convertible promissory notes.

November 25, 2013:

We formed Cardax Acquisition, Inc., a Delaware corporation (“Cardax Sub”), as our wholly owned subsidiary as part of a corporate structure to enable the merger of Cardax Sub with and into Pharma, which would result in our acquisition of the consumer health and pharmaceutical business of Pharma.

February 7, 2014:

We consummated the merger (the “Merger”) of Cardax Sub with and into Pharma, and Pharma became our wholly owned subsidiary.  We divested Koffee Sub and exclusively continued the consumer health and pharmaceutical business of Pharma.  On this date, we amended and restated our certificate of incorporation and bylaws and changed our name to “Cardax, Inc.”

December 30, 2015:

We consummated the merger (the “Holdings Merger”) of Holdings with and into us. There was not any change to our fully diluted capitalization due to the Holdings Merger.

August 24, 2016:

We launched our first commercial product, ZanthoSyn®, a safe anti-inflammatory for general health. ZanthoSyn® is a novel astaxanthin dietary supplement with superior absorption and purity, and is available through our commercial website,